Analysis of tumor-induced lymphangiogenesis and lymphatic vessel invasion of pancreatic carcinoma in the peripheral nerve plexus

Cancer Science

Volumn 103, Issue 10, 2012, Pages 1756-1763

  Cheng, Peng ^a   Jin, Gang ^a   Hu, Xiangui ^a   Shi, Min ^b   Zhang, Yijie ^a   Liu, Rui ^a   Zhou, Yingqi ^a   Shao, Chenghao ^a   Zheng, Jianming ^b   Zhu, Minghua ^b  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 19; MONOCLONAL ANTIBODY D2-40; VASCULOTROPIN C;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH VESSEL METASTASIS; LYMPHANGIOGENESIS; MAJOR CLINICAL STUDY; MALE; NERVE PLEXUS; PANCREAS CARCINOMA; PERIPANCREATIC NERVE PLEXUS; PERIPHERAL NERVE; PRIORITY JOURNAL; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PANCREATIC DUCTAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHANGIOGENESIS; LYMPHATIC METASTASIS; LYMPHATIC VESSELS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PANCREATIC NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 84867233908     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02364.x     Document Type: Article

References (49)

1. Stacker SA, Achen MG, Jussila L, Baldwin ME, Alitalo K. Lymphangiogenesis and cancer metastasis. Nat Rev Cancer 2002; 2: 573-83.
2. Stacker SA, Baldwin ME, Achen MG. The role of tumor lymphangiogenesis in metastatic spread. FASEB J 2002; 16: 922-34.
3. Risau W. Mechanisms of angiogenesis. Nature 1997; 386: 671-4.
4. Ranieri G, Patruno R, Ruggieri E, Montemurro S, Valerio P, Ribatti D. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Curr Med Chem 2006; 13: 1845-57.
5. Rykala J, Przybylowska K, Majsterek I et al. Angiogenesis markers quantification in breast cancer and their correlation with clinicopathological prognostic variables. Pathol Oncol Res 2011; 17: 809-17.
6. von Baumgarten L, Brucker D, Tirniceru A et al. Bevacizumab has differential and dose-dependent effects on glioma blood vessels and tumor cells. Clin Cancer Res 2011; 17: 6192-205.
7. Hirakawa S, Brown LF, Kodama S, Paavonen K, Alitalo K, Detmar M. VEGF-C-induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sites. Blood 2007; 109: 1010-7.
8. Veikkola T, Enholm B, Hytönen M et al. Adenoviral VEGF-C overexpression induces blood vessel enlargement, tortuosity, and leakiness but no sprouting angiogenesis in the skin or mucous membranes. FASEB J 2002; 16: 1041-9.
9. Al-Rawi MA, Jiang WG. Lymphangiogenesis and cancer metastasis. Front Biosci 2011; 16: 723-39.
10. Rasmussen JC, Tan IC, Marshall MV et al. Human lymphatic architecture and dynamic transport imaged using near-infrared fluorescence. Transl Oncol 2010; 3: 362-72.
11. Roma AA, Magi-Galluzzi C, Kral MA, Jin TT, Klein EA, Zhou M. Peritumoral lymphatic invasion is associated with regional lymph node metastases in prostate adenocarcinoma. Mod Pathol 2006; 19: 392-8.
12. Tang RF, Itakura J, Aikawa T et al. Overexpression of lymphangiogenic growth factor VEGF-C in human pancreatic cancer. Pancreas 2001; 22: 285-92.
13. Zampell J, Avraham T, Yoder N et al. Lymphatic function is regulated by a coordinated expression of lymphangiogenic and anti-lymphangiogenic cytokines. Am J Physiol Cell Physiol 2012; 302: C392-404.
14. Skobe M, Hawighorst T, Jackson DG et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 2001; 7: 192-8.
15. Kahn HJ, Bailey D, Marks A. Monoclonal antibody D2-40, a new marker of lymphatic endothelium, reacts with Kaposi's sarcoma and a subset of angiosarcomas. Mod Pathol 2002; 15: 434-40.
16. Liu B, Lu KY. Neural invasion in pancreatic carcinoma. Hepatobiliary Pancreat Dis Int 2002; 1: 469-76.
17. Saad RS, Kordunsky L, Liu YL, Denning KL, Kandil HA, Silverman JF. Lymphatic microvessel density as prognostic marker in colorectal cancer. Mod Pathol 2006; 19: 1317-23.
18. Kurahara H, Takao S, Shinchi H et al. Significance of lymphangiogenesis in primary tumor and draining lymph nodes during lymphatic metastasis of pancreatic head cancer. J Surg Oncol 2010; 102: 809-15.
19. Schmitt AM, Anlauf M, Rousson V et al. WHO 2004 criteria and CK19 are reliable prognostic markers in pancreatic endocrine tumors. Am J Surg Pathol 2007; 31: 1677-82.
20. Chang CC, Yang SH, Chien CC et al. Clinical meaning of age-related expression of fecal cytokeratin 19 in colorectal malignancy. BMC Cancer 2009; 9: 376.
21. Stathopoulos EN, Sanidas E, Kafousi M et al. Detection of CK-19 mRNA-positive cells in the peripheral blood of breast cancer patients with histologically and immunohistochemically negative axillary lymph nodes. Ann Oncol 2005; 16: 240-6.
22. Gradilone A, Gazzaniga P, Silvestri I et al. Detection of CK19, CK20 and EGFR mRNAs in peripheral blood of carcinoma patients: Correlation with clinical stage of disease. Oncol Rep 2003; 10: 217-22.
23. Japan Pancreas Society. Classification of Pancreatic Carcinoma, 2nd English edn. Tokyo: Kanehara Shuppan, 2003.
24. Ohno M, Nakamura T, Kunimoto Y, Nishimura K, Chung-Kang C, Kuroda Y. Lymphagenesis correlates with expression of vascular endothelial growth factor-C in colorectal cancer. Oncol Rep 2003; 10: 939-43.
25. El Demellawy D, Nasr A, Alowami S. Application of CD56, P63 and CK19 immunohistochemistry in the diagnosis of papillary carcinoma of the thyroid. Diagn Pathol 2008; 3: 5.
26. Klapman J, Malafa MP. Early detection of pancreatic cancer: Why, who, and how to screen. Cancer Control 2008; 15: 280-7.
27. Yeo CJ, Abrams RA, Grochow LB et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg 1997; 225: 621-33.
28. Hirai I, Kimura W, Ozawa K et al. Perineural invasion in pancreatic cancer. Pancreas 2002; 24: 15-25.
29. McColl BK, Loughran SJ, Davydova N, Stacker SA, Achen MG. Mechanisms of lymphangiogenesis: targets for blocking the metastatic spread of cancer. Curr Cancer Drug Targets 2005; 5: 561-71.
30. Pour PM, Bell RH, Batra SK. Neural invasion in the staging of pancreatic cancer. Pancreas 2003; 26: 322-5.
31. Makino I, Kitagawa H, Ohta T et al. Nerve plexus invasion in pancreatic cancer: spread patterns on histopathologic and embryological analyses. Pancreas 2008; 37: 358-65.
32. Harrell MI, Iritani BM, Ruddell A. Tumor-induced sentinel lymph node lymphangiogenesis and increased lymph flow precede melanoma metastasis. Am J Pathol 2007; 170: 774-86.
33. Wilting J, Hawighorst T, Hecht M, Christ B, Papoutsi M. Development of lymphatic vessels: tumour lymphangiogenesis and lymphatic invasion. Curr Med Chem 2005; 12: 3043-53.
34. Kodera Y, Katanasaka Y, Kitamura Y et al. Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3. Breast Cancer Res 2011; 13: R66.
35. Kowanetz M, Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res 2006; 12: 5018-22.
36. Yang H, Kim C, Kim MJ et al. Soluble vascular endothelial growth factor receptor-3 suppresses lymphangiogenesis and lymphatic metastasis in bladder cancer. Mol Cancer 2011; 10: 36.
37. Aoki Y, Tosato G. Lymphatic regeneration: New insights from VEGFR-3. J Natl Cancer Inst 2005; 97: 2-3.
38. Stacker SA, Achen MG, Jussila L, Baldwin ME, Alitalo K. Lymphangiogenesis and cancer metastasis. Nat Rev Cancer 2002; 2: 573-83.
39. Goldman J, Rutkowski JM, Shields JD et al. Cooperative and redundant roles of VEGFR-2 and VEGFR-3 signaling in adult lymphangiogenesis. FASEB J 2007; 21: 1003-12.
40. Li R, Younes M, Wheeler TM et al. Expression of vascular endothelial growth factor receptor-3 (VEGFR-3) in human prostate. Prostate 2004; 58: 193-9.
41. Bjorndahl M, Cao R, Nissen LJ et al. Insulin-like growth factors 1 and 2 induce lymphangiogenesis in vivo. Proc Natl Acad Sci USA 2005; 102: 15593-8.
42. Takahashi H, Funahashi H, Sawai H et al. Synthetic serine protease inhibitor, gabexate mesilate, prevents nuclear factor-κB activation and increases TNF-α-mediated apoptosis in human pancreatic cancer cells. Dig Dis Sci 2007; 52: 2646-52.
43. Li R, Wheeler T, Dai H, Ayala G. Neural cell adhesion molecule is upregulated in nerves with prostate cancer invasion. Hum Pathol 2003; 34: 457-61.
44. Demir IE, Ceyhan GO, Liebl F, D'Haese JG, Maak M, Friess H. Neural invasion in pancreatic cancer: the past, present and future. Cancers 2010; 2: 1513-27.
45. Zhu Z, Friess H, diMola FF et al. Nerve growth factor expression correlates with perineural invasion and pain in human pancreatic cancer. J Clin Oncol 1999; 17: 2419.
46. Bockman DE, Büchler M, Beger HG. Interaction of pancreatic ductal carcinoma with nerves leads to nerve damage. Gastroenterology 1994; 107: 219-30.
47. Ito Y, Okada Y, Sato M et al. Expression of glial cell line-derived neurotrophic factor family members and their receptors in pancreatic cancers. Surgery 2005; 138: 788-94.
48. Ceyhan GO, Giese NA, Erkan M et al. The neurotrophic factor artemin promotes pancreatic cancer invasion. Ann Surg 2006; 244: 274-81.
49. Marchesi F, Piemonti L, Fedele G et al. The chemokine receptor CX3CR1 is involved in the neural tropism and malignant behavior of pancreatic ductal adenocarcinoma. Cancer Res 2008; 68: 9060-9.